Clinical trials: Metastatic Malignant Neoplasm
Solid Tumor, Adult, Brain Tumor, Primary
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
This is a first-in-human, open-label, multicenter, dose-escalation, safety, PK, and biomarker study of PBI-200 in subjects with NTRK-fusion-positive advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
- Trial name
- NCT04901806
- Testing
- PBI-200
- Where
- 42 sites in United States, Australia and 9 more
- Volunteers
- 29 people
- Sponsor
- Pyramid Biosciences
Cancer
Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors
The purpose of this study is to test the safety of PRLX 93936 and see what kind of effect it has on patients and their cancer. This study will also determine the highest dose of PRLX 93936 that can be given without causing…
- Trial name
- NCT00528047
- Testing
- PRLX 93936
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Prolexys Pharmaceuticals
Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor
- Trial name
- NCT05099549
- Testing
- AFM24, SNK01
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- NKGen Biotech, Inc.
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- DENALI-1 (NCT06682793)
- Testing
- A2B395, xT CDx with HLA-LOH assay
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- A2 Biotherapeutics Inc.
Renal Cell Carcinoma (RCC)
First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain
This retrospective observational study will use anonymized electronic medical records from the BIG-PAC® database to describe outcomes and treatment management for adults in Spain with advanced or metastatic renal cell carcinoma…
- Trial name
- INSPIRE-RCC (NCT07852884)
- Testing
- First-line systemic regimens
- Where
- Spain
- Volunteers
- 1,200 people
- Sponsor
- Bristol-Myers Squibb
Lung Neoplasm Malignant
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and…
- Trial name
- NCT07286149
- Testing
- MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan
- Where
- 29 sites in United States, Brazil and 9 more
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer, Breast Cancer
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This study is an open, multicenter, dose-escalation and cohort-expansion non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Lutetium [177Lu]…
- Conditions
- Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Solid Tumors
- Trial name
- NCT07274852
- Testing
- Lutetium [177Lu] BL-ARC001
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Testicular Germ Cell Tumors, Metastatic Testicular Germ Cell Tumors
Medical Access Program for DS-9606a (DS-9606) in Patients With Advanced Testicular Germ Cell Tumors
DS-9606a demonstrates antitumor activity in patients with solid tumors known to express CLDN-6, primarily in patients with testicular GCT, with a manageable safety profile with appropriate risk minimization measures.
- Trial name
- NCT07863284
- Testing
- DS-9606a
- Sponsor
- Daiichi Sankyo
Metastatic Cancer, Unresectable Solid Tumor
CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer
Single-center with the option to expand to multi-center, international, open label, non-randomized, multiple-dose, multi-cohort study, in participants with metastatic or unresectable cancer.
- Trial name
- NCT07057349
- Testing
- [18F]CSB-321
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cytosite Biopharma Inc.
Malignant Germ Cell Tumor, Lung Adenocarcinoma
DBC-664 in Adult Patients With Solid Tumors
DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian…
- Conditions
- Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT07705035
- Testing
- DBC-664
- Where
- 7 sites in United States
- Volunteers
- 210 people
- Sponsor
- Duboce Biopharmaceuticals, Inc.
Metastatic Solid Tumors
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).
- Trial name
- NCT04319198
- Testing
- Sacituzumab Govitecan-hiy
- Where
- 21 sites in United States, Belgium and 1 more
- Volunteers
- 25 people
- Sponsor
- Gilead Sciences
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03889899
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Alpha Tau Medical LTD.
Breast Cancer
The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)
This is an open-label, multinational, randomized, multicenter trial designed to compare pegylated liposomal doxorubicin with capecitabine as first line chemotherapy of metastatic breast cancer.
- Trial name
- NCT00266799
- Testing
- Pegylated liposomal doxorubicin (SCH 200746), Capecitabine
- Volunteers
- 210 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer
CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
The objective is to compare the efficacy and safety of CAPOXIRI+BEV therapy versus FOLFOXIRI+BEV therapy as first-line therapy in patients with metastatic colorectal cancer (mCRC).
- Trial name
- QUATTRO-II (NCT04097444)
- Testing
- Bevacizumab, 5-fluorouracil, Leucovorin calcium
- Where
- Japan
- Volunteers
- 112 people
- Sponsor
- Chugai Pharmaceutical
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy…
- Conditions
- Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation
- Trial name
- KEAPSAKE (NCT04265534)
- Testing
- Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy
- Where
- 102 sites in United States
- Volunteers
- 40 people
- Sponsor
- Calithera Biosciences, Inc
Breast Neoplasms
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
The objective of this study was to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone…
- Trial name
- NCT02258464
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Background hormonal therapy
- Where
- 71 sites in United States, Austria and 18 more
- Volunteers
- 99 people
- Sponsor
- Bayer
Triple-Negative Breast Cancer (TNBC), Advanced Triple-Negative Breast Cancer
Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)
This is a first-in-human, multicenter, open-label Phase I/II study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral Zn-Telomir monotherapy in adults with advanced…
- Conditions
- Triple-Negative Breast Cancer (TNBC), Advanced Triple-Negative Breast Cancer, Metastatic Triple-negative Breast Cancer
- Trial name
- NCT07581314
- Testing
- Zn-Telomir
- Volunteers
- 76 people
- Sponsor
- Telomir Pharmaceuticals, Inc.
NSCLC (Non-small Cell Lung Cancer)
Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC
This is a multicenter, randomized, open-label, phase 3 clinical trial designed to evaluate the efficacy and safety of JMKX001899 compared to docetaxel in patients with previously treated, KRAS G12C-mutant advanced or metastatic…
- Trial name
- NCT07242274
- Testing
- JMKX001899, Docetaxel
- Where
- China
- Volunteers
- 472 people
- Sponsor
- Jemincare
Gastric Cancer
A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen
This will be a multi-center, open-label randomized phase 2 study designed to evaluate the progression free survival (PFS) of patients with advanced gastric cancer following treatment with either ARQ 197 or one of three standard…
- Trial name
- NCT01070290
- Testing
- ARQ 197, Oxaliplatin, capecitabine or irinotecan
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00104650
- Testing
- AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
- Volunteers
- 111 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.